Skip to main content

Single Dose of mRNA-1345 Vaccine Safe, Effective Against RSV in Seniors

Medically reviewed by Carmen Pope, BPharm. Last updated on Dec 14, 2023.

By Elana Gotkine HealthDay Reporter

THURSDAY, Dec. 14, 2023 -- A single dose of mRNA-1345 vaccine is safe and results in lower incidence of respiratory syncytial virus (RSV)-associated disease in older patients, according to a study published in the Dec. 14 issue of the New England Journal of Medicine.

Eleanor Wilson, M.D., from Moderna in Cambridge, Massachusetts, and colleagues conducted a randomized, phase 2 to 3 trial in which adults aged 60 years of age or older were randomly assigned to receive one dose of mRNA-1345 (50 μg; 17,793 participants) or placebo (17,748 participants).

Participants were followed for a median of 112 days. The researchers found that vaccine efficacy was 83.7 and 82.4 percent against RSV-associated lower respiratory tract disease with at least two signs or symptoms and against the disease with at least three signs or symptoms, respectively. Vaccine efficacy against RSV-associated acute respiratory disease was 68.4 percent. Protection was seen against RSV subtypes A and B and was mainly consistent across subgroups defined according to age and coexisting conditions. Compared with those in the placebo group, participants in the mRNA-1345 group had a higher incidence of solicited local adverse reactions (58.7 versus 16.2 percent) and of systemic adverse reactions (47.7 versus 32.9 percent); most reactions were mild-to-moderate and transient. Overall, 2.8 percent of each trial group had serious adverse events.

"This phase 2 to 3 efficacy trial showed that a single 50-μg dose of the mRNA-1345 vaccine in adults 60 years of age or older was efficacious against a spectrum of RSV-confirmed respiratory disease," the authors write

The study was funded by Moderna, the manufacturer of the mRNA-1345 vaccine.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted December 2023

Read this next

Personalized Tool Can Predict Infants at Increased Risk for RSV

THURSDAY, May 9, 2024 -- A personalized tool can predict infants at increased risk for severe respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI) who would...

SARS-CoV-2 Vaccine Does Not Increase New-Onset Seizure Risk

TUESDAY, April 30, 2024 -- There is no risk for new-onset seizure incidence for individuals receiving a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine versus...

Most Moms-to-Be Interested in RSV Vaccination During Pregnancy

THURSDAY, April 25, 2024 -- More than half of women who are pregnant or planning to become pregnant are very likely to get vaccinated against respiratory syncytial virus (RSV)...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.